Growth Accelerated By Emerging New Applications In Complement Related Diseases
 |
| Plasma Protease C1-Inhibitor Treatment Market |
Plasma protease C1-inhibitor treatment is used for treating hereditary angioedema (HAE), a rare genetic condition characterized by recurrent episodes of severe swelling in different body parts. C1-inhibitor helps in regulating the system associated with inflammation and complement activation. It provides relief from symptoms associated with HAE attacks by preventing enzymes from activating the complement system and causing swelling.
The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Emerging new applications of C1-inhibitor in treating complement related disorders such as autoimmune diseases, ischemia-reperfusion injury and transplant rejection is expected to drive the market growth over the forecast period. Increasing research focus on evaluating the efficacy of C1-inhibitor in different complement-mediated conditions has generated positive pre-clinical and clinical trial results. For instance, in 2021, KalVista Pharmaceuticals announced positive results from a Phase 2 clinical trial evaluating KVD900, an oral C1-inhibitor for treatment of attacks associated with HAE. If approved, KVD900 will be the first oral therapy option for patients and help in improving treatment convenience. These new developments are expanding the clinical applications of C1-inhibitor which is anticipated to fuel the plasma protease C1-inhibitor treatment market growth during the forecast period.
Segment Analysis
The global plasma protease C1-inhibitor treatment market is segmented by type into C1-inhibitor (human) recombinant and C1-inhibitor (human) plasma-derived. Currently, the C1-inhibitor (human) plasma-derived segment accounts for the majority of the market share owing to its proven efficacy and safety profile. However, the C1-inhibitor (human) recombinant segment is expected to grow at a higher rate during the forecast period due to its reliable supply chain and fewer concerns regarding infectious diseases.
Key Takeaways
The Global Plasma Protease C1-Inhibitor Treatment Market Demand is expected to witness high growth during the forecast period from 2023 to 2030. The market size is projected to reach US$ 5432.28 Mn by 2030, expanding at a CAGR of around 18%.
Regional analysis
North America currently accounts for the largest share of the global plasma protease C1-inhibitor treatment market due to high patient awareness levels and developed healthcare infrastructure in the region. However, Asia Pacific is anticipated to register the fastest growth over the forecast period driven by rising healthcare expenditure, increasing patient pool, and growing adoption of novel therapies in emerging countries like China and India.
Key players
Key players operating in the plasma protease C1-inhibitor treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring LLC and Takeda Pharmaceutical Company Limited currently dominate the market owing to their well-established commercialization and distribution networks.
Explore more information on this topic, Please visit-
Comments
Post a Comment